Inclusion criteria: This is a Phase I open label multi-center study to evaluate the safety, tolerability, of the investigational drug MYTX-011 in patients with locally advanced, recurrent or metastatic NSCLC. KisMET-0 study.
- Histologically or cytologically confirmed locally advanced, recurrent or metastatic NSCLC and have received available standard of care therapy.
- There is no limit on the number of prior therapies that can have been received.
- Known to not have an actionable EGFR mutation. Subjects with or without other driver mutations are permitted to enroll.
Sponsor/Collaborator: Mythic Therapeutics
Contact and Locations:
Name: William T Downing
Phone Number: 1-833-888-1138
Email: clinicalsupport@mythictx.com
55 Locations (worldwide): https://www.clinicaltrials.gov/study/NCT05652868#contacts-and-locations
Mechanism of action: MYTX-011 is in a class of medications called antibody drug conjugates (ADCs). MYTX-011 is composed of an anti-cMET antibody and the potent antimicrotubule drug monomethyl auristatin E (MMAE).
Phases: Phase 1
NCT Number: NCT05652868
Status: Recruiting
